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Endovascular aneurysm repair reverses the
increased titer and the inflammatory activity of
interleukin-1 in the serum of patients with
abdominal aortic aneurysm
Clara M. Yates, PhD,a Mohamed Abdelhamid, MSc, MRCSEd,b Donald J. Adam, MD, FRCSEd,b
Gerard B. Nash, PhD,a Andrew W. Bradbury, BSc, MBA, MD, FRCSEd,b and
G. Ed Rainger, PhD,a Birmingham and Solihull, West Midlands, United Kingdom
Objective: To examine serum cytokine/chemokine profiles before and 6 months after endovascular repair (EVAR) of
abdominal aortic aneurysm (AAA) and to determine whether they correlate with serum inflammatory activity using an in
vitro model of leukocyte recruitment.
Methods: Serum IL-1-, IL-1, IL-4, IL-6, IL-8, IL-10, IFN-, IP-10, MCP-1, TNF-, and TNF-were measured using
a cytometry-based immunoassay. To test patient serum for direct inflammatory activity, human endothelial cells (EC)
were stimulated with 30% patient serum for 24 hours. To test patient serum for the ability to prime EC for inflammatory
responses, EC were incubated with 30% patient serum for 24 hours, followed by stimulation with low-dose (5 U/mL)
TNF for 4 hours. Under both regimens of stimulation, the degree of EC activation was assessed by assaying neutrophil
recruitment in a flow-based model.
Results: Only IL-1 (67.9  10.4 pg/mL vs 41.9  7.4 pg/mL) and IL-8 (51.5  5.1 vs 32.6  4.7 pg/mL) changed
significantly after surgery. Patient serum alone was unable to activate EC. However, serum from both time points could
prime EC responses to low-dose TNF. Thus, after priming with preoperative serum, EC stimulated with TNF could
recruit 76.7 12.0 neutrophils/mm2 into the subendothelial cell space. Post-EVAR serumwas significantly less effective
(44.4 10.2 neutrophils/mm2). This reduction in neutrophil recruitment correlated with reduced IL-1 in post-EVAR
serum. The addition of a neutralizing antibody against IL-1 to pre-EVAR serum inhibited EC priming and neutrophil
recruitment, strongly implying that this cytokine was the priming agent.
Conclusion: EVAR reduces serum IL-1 and its inflammatory activity in patient serum. IL-1 is, therefore, implicated in
the molecular pathology of AAAs and may have potential as a clinically useful biomarker. ( J Vasc Surg 2011;54:
497-503.)
Clinical Relevance:Continuing uncertainty exists over which patients will benefit from abdominal aortic aneurysm (AAA)
repair in addition to medical therapy as well as which repair method, open or endovascular, is the most clinically and
cost-effective. Greater understanding of AAA development and progression, and the subsequent identification of
biomarkers for rupture risk, are likely to result in better selection of patients for intervention and provide better measures
of successful repair. These novel data implicate interleukin (IL)-1 in the molecular pathology of AAA. Further, they
suggest that IL-1 may be a predictive biomarker for AAA size as well as outcome after endovascular aneurysm repair.
l
p
o
s
5
t
r
l
i
c
a
i
E
n
l
oWith respect to the management of abdominal aortic
aneurysms (AAAs), it is widely believed that the risks of
repair generally outweigh the risks of continued surveil-
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doi:10.1016/j.jvs.2011.02.061ance until the AAA reaches 5.5 cm in maximum anterior-
osterior (AP) diameter; most vascular surgeons will not
ffer repair of asymptomatic AAAs until they exceed this
ize.1-3 However, the natural history of AAAs greater than
.5 cm remains incompletely defined. Currently, there is no
est or investigation that can accurately quantify the risks of
upture on an individual patient basis and there is a lack of
evel 1 data from randomized controlled trials to guide
ntervention in this group.4
In patients fit for both open repair (OR) and endovas-
ular aneurysm repair (EVAR), the latter is associated with
significant reduction in short-term morbidity and mortal-
ty.5-7 However, there remain serious questions regarding
VAR in terms of protection from AAA rupture and the
eed for reintervention, and all patients so treated require
ifelong surveillance. It is uncertain whether the retention
f biologically active mural thrombus and its ongoing
erfusion through so-called type 2 endoleaks contributes to
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August 2011498 Yates et aldevice and clinical failure. Surprisingly, there are no data
available on the long-term effects of EVAR on systemic
inflammatory mediators that might be useful markers of
disease activity after EVAR.
As well as ongoing uncertainty over which patients will
benefit from AAA repair, and which method (OR or
EVAR) is most clinically and cost-effective, the pathophys-
iology of AAAs remains poorly understood.8 A fuller un-
derstanding of the complex biology underlying AAA devel-
opment, progression, and rupture would probably result in
better selection of patients for intervention (OR or EVAR)
and a better appreciation of whether that intervention has
been successful in arresting, or reversing, the aneurysmal
process. To that end, the aim of the current study was to
determine which cytokines and chemokines were elevated
in the serum of patients with AAAs, whether these changed
following EVAR, and to examine the impact of those
changes upon neutrophil adhesion to serum-activated en-
dothelial cells (EC) as a bioassay of the systemic inflamma-
tory status of the patient.
METHODS
Patients and collection of serum. Ethical approval
and fully informed, written consent were obtained from all
subjects. We studied 17 patients of mean (range) age 80
(69-88) years undergoing elective EVAR for asymptomatic
AAAs of mean (range) AP diameter of 6.6 (5.4-10.0) cm.
Four patients had fenestrated EVAR for juxtarenal AAAs;
the rest underwent repair of infrarenal AAAs with a stan-
dard EVAR device. Six months postoperatively, there were
no incidences of endoleak, and 16 of 17 patients exhibited
a reduction in the diameter of their aneurysm (Table I). All
Table I. Endoleak status of patients following EVAR,
aneurysm size pre- and postoperatively, mural thrombus
volume preoperatively
Patient Endoleak
Size (cm)
Mural thrombus (vol)Pre Post
1 No 10 7.8 315.7
2 No 7 5.8 156.6
3 No 5.8 5.3 137.3
4 No 5.7 5.4 97.6
5 No 6.1 5.7 63.3
6 No 6.5 5.5 125.4
7 No 6.6 6.6 ND
8 No 10 9 ND
9 No 6.5 5.7 ND
10 No 6 4.7 136.7
11 No 5.7 5.3 92.5
12 No 6 5.8 101.3
13 No 7.6 5.1 ND
14 No 5.4 4.8 ND
15 No 8 7.5 ND
16 No 7.5 6.3 63.3
17 No 6 4.1 70.9
EVAR, Endovascular aneurysm repair; ND, not done, equipment unavail-
able at Selly Oak Hospital.patients remained on the same medication pre- and post- lperatively. The control cohort comprised eight patients of
ean (range) age 73 (65-89) years without an AAA as
roven by computerized tomography (CT) scan performed
or another indication. Cardiovascular risk factors for the
ontrol cohort and indications for CT scan are detailed in
able II. Blood was collected into vacuette Z Serum Sep
lot activator tubes (Greiner Bio One, Frickenhausen,
ermany) before and 6 months after EVAR. Serum was
solated via centrifugation, aliquoted, and stored until use
t 80°C.
Measurement of serum cytokines and chemokines.
Milliplex MAP immunoassay (Millipore, Billerica, Mass)
ased on the Luminex bead system (LX100 machine; Lu-
inex Corp, Austin, Tex; and STarStation software; ACS,
heffield, United Kingdom) was used to determine the
erum concentrations of interleukin (IL)-1-, IL-1, IL-4,
L-6, IL-8, IL-10, interferon (IFN)-, CXCL10 (IP-10),
CL2 (monocyte chemotactic protein; MCP-1), tumor
ecrosis factor (TNF)-, and TNF-.
Endothelial cell isolation and culture. Human um-
ilical vein ECs were isolated as previously described9 and
ultured in M199 (Gibco Invitrogen Compounds, Paisley,
nited Kingdom) supplemented with 10 ng/mL epider-
al growth factor, 35 g/mL gentamicin, 1 g/mL hy-
rocortisone (all from Sigma, Paisley, United Kingdom),
.5 g/mL amphotericin B (Gibco Invitrogen Com-
ounds), and 20% fetal calf serum (FCS) (Sigma). Primary
ells were subcultured into six-channel -Slide VI flow
hambers (Ibidi, Munich, Germany) until confluent. Con-
uent EC were cultured for 24 hours with medium in
hich FCS was substituted for 30% serum from patients or
ged-matched controls. EC cultured continuously in 20%
CS served as an additional control. ECs were then stimu-
able II. Cardiovascular risk and indication for CT scan
or the control cohort
ontrol CV risk Indication for CT scan
None Routine postcolectomy follow-
up, had colectomy 2 years ago
for colon cancer
None Routine postcolectomy follow-
up, had colectomy 2 years ago
for colon cancer
None Abdominal pain, no abnormality
detected
Ischemic heart
disease/
hypertension
Routine postcolectomy follow-
up, had colectomy 2 years ago
for colon cancer
Hypertension Routine postcolectomy follow-
up, had colectomy 2 years ago
for colon cancer
None Routine postcolectomy follow-
up, had colectomy 2 years ago
for colon cancer
Hypertension/
diabetes mellitus
Abdominal pain, no abnormality
detected
None Renal cysts
T, Computerized tomography.ated with 5 U/mL TNF (Sigma) for the final 4 hours of
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Volume 54, Number 2 Yates et al 499culture before flow assay. In some experiments, function-
neutralizing antibodies against IL-1 or IL-8 (10 g/mL,
both from R&D Systems, Abingdon, United Kingdom)
were added to patient serum prior to addition to culture
medium.
Flow-based adhesion assay. Neutrophils were isolated
from the blood of healthy donors, none of whomwere smok-
ers, by density-gradient centrifugation (Histopaque-1077 and
Histopaque-1119; Sigma) and suspended in phosphate-
buffered saline containing 0.1% bovine serum albumin
(Sigma) (PBS/Alb). Six-channel -Slide VI flow chambers
were mounted on a phase-contrast video microscope (In-
verted Labovert; Leitz, Stamford, Conn) (Fig 1). Neutro-
phils were perfused across EC at 106 cells/mL at a wall
shear stress of 0.05Pa for 4 minutes, followed by wash
buffer (PBS/Alb) to remove nonadherent cells. Video re-
cordings of 8 to 10 fields along the center of the channel
were made between 2 and 4 minutes of perfusion of wash
buffer.
Records were digitized using Image-Pro Plus (Media-
Cybernetics, Bethesda, Md) and analyzed for cell behavior.
The following parameters were evaluated: total numbers of
neutrophils captured by ECs from flow expressed as abso-
lute adhesion per mm2 per 106 cells perfused; the propor-
tions (expressed as a percentage) of these adherent cells that
rolled (phase bright spherical cells, revolving slowly over
the surface), became stably adherent (phase bright, station-
ary cells typically spreading on the surface) or which trans-
migrate through the endothelial monolayer (phase-dark,
spread cells migrating under the endothelial cells). In some
analyses, the absolute number of transmigrated cells was
also assessed.
Statistics. Variation between multiple treatments was
evaluated using analysis of variance (ANOVA), followed by
Fig 1. The flow-based adhesion assay. Schematic diagram illus-
trating the flow-based adhesion assay: Ibidi slides containing en-
dothelial cells were mounted on the stage of a video microscope
and attached via silicon tubing to a 50-mL glass syringe and an
electronic switching valve. Isolated neutrophils or PBS/Alb were
perfused through the slides at a wall shear stress of 0.05 Pa.
Experiments were conducted in a 37°C Perspex cabinet and video
recordings made.Bonferroni’s multiple comparison test, and differences be- wween individual treatments were evaluated by paired t test.
orrelation coefficient was calculated using GraphPad sta-
istical analysis tools. Data are presented as mean  SEM.
ESULTS
Changes in serum cytokines and chemokines fol-
owing EVAR. Serum cytokine and chemokine concen-
rations before and 6 months after EVAR are shown in Fig
, A. IL-4 was not detectable. IFN-, IL-1, IL-10,
NF-, and TNF- were detectable at low levels (10
g/mL) but did not change significantly after EVAR. IL-6
ig 2. Cytokine and chemokine expression in patient serum fol-
owing endovascular aneurysm repair (EVAR). A, Levels of 10
ytokines and chemokines in pre- and postoperative patient serum
ere measured using luminex. B, Correlation of the levels of
nterleukin (IL)-1 in preoperative serum with preoperative aneu-
ysm size. C, Correlation of the levels of IL-8 in preoperative
erum with preoperative aneurysm size. *P  .05, **P  .01 for
omparison between pre- and postsurgery. AAA, Abdominal aor-
ic aneurysm.as more abundant ( 50 pg/mL), but again, did not
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August 2011500 Yates et alchange after EVAR. IP10 (CXCL10) and MCP-1 (CCL2)
were present in high concentrations of 1 and 2.5 ng/
mL, respectively. These levels were maintained 6 months
post-EVAR. IL-1 and IL-8 were of particular interest, as
they were present at relatively high concentrations (50-100
pg/mL) preoperatively but had fallen significantly by 6
months. Interestingly, preoperative levels of IL-1 posi-
tively correlated with the preoperative size of patients’
aneurysms (Fig 2, B), whereas there was no correlation with
preoperative levels of IL-8 (Fig 2, C).
Effect of patient serum or TNF on neutrophil ad-
hesion to cultured EC. Pretreatment for 24 hours with
pre- or postoperative patient serum did not result in adhe-
sion of neutrophils to EC unstimulated with TNF (Fig 3,
A). However, ECs stimulated with either 5 U/mL or 100
U/mL TNF for 4 hours supported the adhesion of sub-
stantial numbers of neutrophils (Fig 3, A). Furthermore,
following stimulation with 100 U/mL TNF most neutro-
phils were either firmly adherent to, or had migrated
through, the endothelial monolayer (Fig 3, B). By compar-
Fig 3. Patient serum does not induce endothelial cell activation.
A, Adhesion of neutrophils to endothelial cells that were un-
treated, treated with 5 U/mL or 100 U/mL tumor necrosis factor
(TNF) for 4 hours as a control or pretreated with pre- or postop-
erative patient serum for 24 hours. B, Behavior of recruited neu-
trophils to endothelial cells stimulated with 5 or 100 U/mL TNF
for 4 hours 	 rolling; 	 firmly adherent; 	 transmi-
grated. There is a significant decrease in the proportion of neutro-
phils rolling on endothelial cells stimulated with 100 U/mL
compared with 5 U/mL TNF and a significantly higher level of
transmigrated neutrophils. *P  .05, **P  .01.ison, following stimulation with 5 U/mL TNF, a greater troportion were rolling and significantly fewer neutrophils
ad transmigrated (Fig 3, B). Figure 4 shows typical pho-
omicrographs of ECs treated with low- or high-dose TNF
r pre- or post-EVAR patient serum.
Effect of patient serum on neutrophil adhesion to
ultured EC in the presence of TNF. Although patient
erum did not directly stimulate cultured EC to recruit
owing neutrophils, the incubation of ECs with preopera-
ive serum primed these cells for responses to low-dose (5
/mL) TNF. There was a nonsignificant trend to in-
reased neutrophil adhesion in the presence of both pre-
nd post-EVAR patient serum when compared with serum
rom the control cohort (Fig 5, A). However, following
retreatment with preoperative serum, there was a highly
ignificant increase in neutrophil transmigration in the
resence of 5 U/mL TNF when compared with post-
VAR and control serum (Fig 5, B). This suggests that the
gent in the preoperative serum, which primed endothelial
ells for more efficient neutrophil transmigration, was no
onger present 6 months after EVAR.
Effect of IL-1 neutralization on neutrophil
ransmigration. The addition of a nonspecific IgG con-
rol antibody, or an IL-8 neutralizing antibody, had no
ffect on the ability of preoperative patient sera to prime
Cs for neutrophil transmigration (Fig 6). However, the
ddition of an IL-1 neutralizing antibody reduced neu-
rophil transmigration to levels seen with postoperative
atient sera tested in parallel in the same experiments.
ISCUSSION
The cellular and molecular pathology of AAAs is poorly
nderstood, and this lack of knowledge hampers the ability
ig 4. Neutrophil behavior on endothelial cells. Neutrophils re-
ruited to endothelial cells treated with (A) 5 U/mL tumor
ecrosis factor (TNF), (B) 100 U/mL TNF, (C) Pre-op, and (D)
ost-op serum. Phase bright cells are rolling or firmly adherent to
he endothelial cell surface, transmigrated neutrophils are phase
ark and underneath the endothelial cell monolayer. R, Rolling
eutrophils; SA, surface-adherent neutrophils; TM, transmigrated
eutrophils.o stratify patients according to clinical risk or to predict
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Volume 54, Number 2 Yates et al 501outcomes of intervention. In the current study, we aimed
to describe mediators of inflammation in the circulation of
patients with large AAAs (
5.5 cm) and to determine
whether these agents were systemically active. The main
and novel findings of the present study were that the serum
of patients with AAAs is constitutively stimulatory for en-
dothelial cells and leads to an amplified response to a
secondary inflammatory challenge, so that the efficiency of
neutrophil recruitment is significantly increased in an in
vitro flow-based adhesion assay. Surgical intervention re-
versed the stimulatory capability of patient serum and a
reduction in IL-1 following EVAR appears to be respon-
sible. Thus, IL-1 levels were high preoperatively and were
significantly reduced at 6 months following EVAR. Pre-
but not post-EVAR patient serum primed endothelial cells
Fig 5. Preoperative serum primes endothelial responses to low-
dose tumor necrosis factor (TNF) resulting in altered neutrophil
behavior. Control and patient serumwas used to prime endothelial
cells for 24 hours and 5 U/mL TNF added for the final 4 hours.
Total neutrophil adhesion was assessed (A) and levels of neutrophil
transmigration quantified (B). There is a significant difference
between levels of transmigrated neutrophils on control vs preop-
erative serum. There is a significant inhibition of neutrophil trans-
migration on endothelial cells cultured with postoperative serum
compared with preoperative serum. *P  .05, **P  .01.for increased neutrophil transmigration in response to low pose TNF, and this priming function was completely abol-
shed by antibody blockade of IL-1 activity in preopera-
ive serum.
Several other groups have measured inflammatory me-
iators in the serum of AAA patients prior to surgery.10,11
rofiles for patients with stable and ruptured aneurysms
ave been described, and in some studies, direct compari-
ons between these patient groups were conducted.12-15
owever, here we screened the serum of AAA patients
efore and after surgical repair by the EVAR technique with
6-month period between collection of samples. A number
f inflammatory mediators were detectable, although only
L-8 and IL-1 were sensitive to the surgical intervention,
e, decreased significantly after EVAR. Previous studies
ave aimed to determine circulating cytokine levels in AAA
atient serum after surgery. Norgren et al16 measured levels
f TNF-, IL-6, and IL-8 in EVAR patients preoperatively,
4 hours postoperatively, and 7 days postoperatively. Lev-
ls of each increased following surgical insult, as expected,
ut returned to baseline by 7 days. Pardoi et al,17 measured
L-8 by ELISA in EVAR patients presurgery, and up to 72
ours following surgery, finding that levels increased im-
ediately after surgery, and fell by 72 hours, although not
o preoperative levels. Comparisons of cytokine levels in-
uced by OR and EVAR have also been made, demonstrat-
ng that the less-invasive EVAR technique is associated with
ower levels of IL-6 and TNF- over a 5-day regimen of
ampling.18,19 Importantly, all of the above studies have
racked the changes in cytokine titer during and for a short
eriod after surgery, when their release by surgical trauma
ill mask any underlying improvement of the disease-
ssociated cytokine profile. To our knowledge, the current
tudy is the first to track serum cytokine levels, and, there-
ore, levels of systemic inflammation, over a longer-term
ollow-up. In addition, it is the first to demonstrate IL-1 is
ig 6. Neutralizing interleukin (IL)-1 inhibits endothelial cell
riming by preoperative serum. Neutralization of IL-1 in the
resence of preoperative serum reduces neutrophil transmigration
cross endothelial cells pretreated with preoperative serum. IgG
ontrol antibody and anti-IL-8 had no effect on neutrophil trans-
igration. P  .001.resent in the preoperative serum of AAA patients and that
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August 2011502 Yates et althe systemic levels of this agent are sensitive to surgical
intervention.
IL-1 is a member of the interleukin superfamily syn-
thesized as a 33-kDa protein, pro-IL-1, which is cleaved
by the enzyme calpain to yield a 17-kDa peptide of mature
IL-1 (mIL-1).20 Both forms are biologically active and
bind with similar affinity to, and signal via, the IL-1 recep-
tor (IL-1R).21,22 This results in translocation of the tran-
scription factor NF-B to the nucleus leading to inflamma-
tory gene transcription.23 It has been previously shown that
overexpression of pro-IL-1 in endothelial cells leads to
enhanced TNF-induced CXCL2 (monocyte inflammatory
protein-2 [MIP-2]; also known as GRO) secretion, sup-
porting the concept that IL-1 has the potential to prime
endothelial responses for subsequent response to TNF.
However, the majority of pro-IL-1 is found in the plasma
membrane or the nucleus of cells,24 and it is not found in
the serum of healthy people, as mIL-1 is usually only
released extracellularly upon cell death.25 Thus, although
IL-1 is expressed by cells associated with pathology of
AAA, ie, in platelets,26 and in activated monocytes/macro-
phages,25,27 its presence in preoperative serum was a sur-
prising observation. However, as we were able to measure
significant levels of IL-1 in serum, we hypothesized that it
was responsible for the priming response to low dose TNF
observed in cultured EC. This mechanism of endothelial
excitation was confirmed by using a function neutralizing
antibody to ablate that activity of IL-1 in preoperative
serum. Thus, the presence of high titers of IL-1 in patient
serum, positive correlation with preoperative AAA size, and
the significant reductions observed after surgery, indicate
that this cytokine might be a marker of successful surgical
outcome. Additionally, IL-1 could potentially be used to
track disease risk, progression, and associated complica-
tions in longer-term follow-up. Moreover, the involvement
of IL-1 in driving endothelial cell inflammation indicates
that this cytokine is involved in the molecular pathology of
AAAs, and, thus, it could have potential as a biomarker
of disease behavior and/or development prior to the point
of surgical intervention. Future trials are required to vali-
date these hypotheses. One might also speculate that treat-
ment strategies based on neutralizing the biologic effects of
IL-1 might be of value in halting the development and
progression of AAAs in susceptible individuals.28
IL-8 (CXCL-8), the serum concentration of which also
consistently dropped after EVAR, is a member of the CXC
family of chemokines and a major regulator of neutrophil
recruitment and migration.29 IL-8 signals via neutrophil
CXCR1 and CXCR2, activating neutrophil integrins which
in turn bind ICAM-1 on the endothelial cell surface result-
ing in firm neutrophil adhesion.30 It would not be unrea-
sonable to hypothesize that the postoperative reduction in
serum IL-8 may have contributed to the decrease in neu-
trophil transmigration observed in our in vitro flow assay.
However, antibody blockade of IL-8 in preoperative serum
had no effect on levels of transmigration, indicating that
IL-8 was not responsible for the increase in neutrophil
recruitment evident in our experiments. Nevertheless, theeduction in IL-8 in serum between pre- and postoperative
eriods was so consistent that IL-8 may be of use as a
otential biomarker. Indeed, a previous study using 90
atients showed a weak but significant correlation of IL-8
ith AAA development, although we did not observe a
elationship between IL-8 levels and aneurysm size.12
here is potential that a multivariate analysis of the levels of
L-8 in alliance with other agents such as IL-1, may have
tility in tracking disease progression, as well as providing
nformation on long-term outcome of the EVAR process.
gain, trials-based data are required to confirm this hy-
othesis.
In fact, there have been numerous small trials in AAA
atients (usually less than 100 subjects), which have iden-
ified soluble molecules in the blood plasma as circulating
iomarkers of aneurysm size, rate of progression of disease,
nd/or likelihood of aortic rupture.31 These include cyto-
ines and chemokines (eg, IL-6, IL-8, and TNF-), acute
hase reactants (C-reactive protein and fibrinogen), degra-
ation products of vessel wall matrix components (eg,
eptides from elastin and collagen), and proteases (eg,
MP9 and elastase). Due to the limited powering of these
tudies, associations are generally weak and few (if any)
ave considered the utility of multivariate biomarker anal-
sis in assessment of patients. Importantly, none of these
tudies has considered using soluble biomarkers to assess
he success and/or long-term outcome of surgery. There is
clear need for an inexpensive and rapid laboratory-based
ssay for stratifying patients based on risk of rupture and
eed for surgery. In addition, a means of tracking immedi-
te and long-term success of surgical intervention could
reatly reduce morbidity and mortality associated with
dverse outcomes. Thus, we conclude that as IL-1 is
ensitive to clinical intervention in AAA patients, it is pos-
ible that it could be used in such a context, possibly in
ssociation with other blood borne markers of disease
ctivity (see above for details). However, further studies are
equired to demonstrate its usefulness in this context.
Umbilical cords for endothelial cell isolation were col-
ected with the assistance of the Birmingham Women’s
ealth Care NHS Trust.
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